Aurobindo Pharma receives EIR for Sterile Drug Formulation Facility from US FDA

Aurobindo Pharma Ltd is pleased to announce that it has received the Establishment Inspection Report (EIR) from the US FDA stating their acceptance on Aurobindo's **sterile injectable formulation facility** in Chitkul Village, near Hyderabad, India.

This is the third successive USFDA approval for Unit–6 (the other approvals being for the formulation orals manufacturing facility and the sterile - API manufacturing facility).

AUROBINDO PHARMA LTD

Aurobindo Pharma Limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The Company has received approvals for most of the targeted API and formulation facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa.

The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries.